After studying engineering, Editor-In-Chief Phil Greenfield started reporting on the medtech sector as a science journalist in 1993, when digital health, TAVR and personalized medicine were pipe dreams. He has since worked across all areas of health-care publishing, as an editor, publisher and principal analyst, and has been responsible for launching intelligence-based products to medtech and pharma clients. Phil has written extensively on topics around diagnostic imaging, IVDs, cardiovascular devices, orthopedics, oncology, wound care, clinical trials and EU reimbursement, and has authored numerous market forecasting reports on subjects ranging from prostate cancer diagnostics and devices to transcatheter embolization systems. Phil has also recently worked as an independent consultant with medtech/healthtech companies and universities assessing markets and product opportunities. A keen cyclist and walker, he lives in Yorkshire, England, where the steep hills help him counterbalance his other loves of food and Belgian beer.
Latest From Phil Greenfield
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.
The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.
The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.
One of the few silver linings in a tumultuous year dominated by a global pandemic was the huge boost given to the diagnostics and telehealth sectors. But while new technologies for rapid testing for COVID-19 and remote monitoring tools dominated the headlines, there were also key developments in robotic surgery, early-stage cancer testing and cardiac arrhythmia treatment. Here are Medtech Insight’s most popular R&D stories in 2020.
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.
The COVID-19 pandemic has accelerated development of another new molecular diagnostic technology.